- Conditions
- Retinitis Pigmentosa
- Interventions
- ADX-2191
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Proliferative Vitreoretinopathy
- Interventions
- ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
- Drug · Other
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
- Conditions
- Primary Vitreoretinal Lymphoma
- Interventions
- ICM ADX-2191 injection, Monthly ADX-2191 injection
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida